A panel of Australia’s top endocrinologists took to the stage to debate the best second-line treatment options for type 2 diabetes. But was it insulin, GLP-1 analogues, SGLT-2 inhibitors, sulphonylureas, glitazones or DPP-4 inhibitors that won the audience vote? Professor Steven Colagiuri – Insulin “Don’t use insulin as a threat” Director of The Boden Institute ...
Type 2 diabetes
The great debate: What’s your second-line drug of choice?
By Kate Marsh
31 Aug 2015